LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

PerkinElmer Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-8.6M

47M

Ventes

-21M

699M

P/E

Moyenne du Secteur

52.799

80.03

BPA

1.18

Rendement du dividende

0.27

Marge bénéficiaire

6.675

Employés

11,000

EBITDA

-14M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.46% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.27%

2.29%

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

612M

12B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

29%

71%

78 / 374 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 déc. 2025, 23:21 UTC

Résultats
Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 déc. 2025, 23:14 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 déc. 2025, 22:01 UTC

Principaux Mouvements du Marché

Costco Wholesale Reports Higher Monthly Sales

3 déc. 2025, 21:38 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 déc. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 déc. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 déc. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 déc. 2025, 23:10 UTC

Résultats

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 déc. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 déc. 2025, 23:06 UTC

Acquisitions, Fusions, Rachats

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

EQB to Buy PC Financial From Loblaw for About $573.5M

3 déc. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 déc. 2025, 22:20 UTC

Résultats

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 déc. 2025, 22:19 UTC

Résultats

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 déc. 2025, 22:17 UTC

Résultats

Salesforce Working to Add Voice to Agentforce, CEO Says

3 déc. 2025, 22:16 UTC

Résultats

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 déc. 2025, 22:15 UTC

Résultats

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 déc. 2025, 22:10 UTC

Acquisitions, Fusions, Rachats

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 déc. 2025, 22:09 UTC

Acquisitions, Fusions, Rachats

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 déc. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 déc. 2025, 21:49 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:23 UTC

Résultats

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 déc. 2025, 21:19 UTC

Résultats

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:06 UTC

Résultats

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 déc. 2025, 21:04 UTC

Résultats

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 déc. 2025, 21:03 UTC

Résultats

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

8.46% hausse

Prévisions sur 12 Mois

Moyen 111.1 USD  8.46%

Haut 125 USD

Bas 100 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

8

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

78 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat